Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 13/20 | 0.47 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | DHODH | Q02127 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 9/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | METAP2 | P50579 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.37 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1231724 | 0.88 | MAPK10 (0.46) | MAPK10MAPK9RAB9ADHODHHDAC6 | |
| SCHEMBL12901056 | 0.86 | MAPK10 (0.58) | MAPK10MAPK9RAB9AMAPK8 | |
| SCHEMBL12900858 | 0.85 | MAPK10 (0.48) | MAPK10MAPK9DHODHHDAC6MAPK8 | |
| SCHEMBL1231892 | 0.75 | MAPK9 (0.52) | MAPK10MAPK9 | |
| SCHEMBL1231881 | 0.75 | MAPK10 (0.64) | MAPK10MAPK9 | |
| SCHEMBL12900855 | 0.75 | MAPK10 (0.45) | MAPK10MAPK9MAPK8 | |
| SCHEMBL12901776 | 0.74 | CYP1A2 (0.41) | MAPK10MAPK9DHODHHDAC6MAPK8 | |
| SCHEMBL28001490 | 0.74 | NFE2L2 (0.44) | RAB9ADHODHHDAC6TACR1 | |
| SCHEMBL1230848 | 0.74 | MAPK10 (0.57) | MAPK10MAPK9MAPK8 | |
| SCHEMBL12900283 | 0.73 | MAPK10 (0.66) | MAPK10MAPK9MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046121-A1 | INHIBITORS OF FOCAL ADHESION KINASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046121-A1 | INHIBITORS OF FOCAL ADHESION KINASE | PTK2, CABLES1, TNK2 | MAPK10 590/4885MAPK9 239/4885RAB9A 2475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.